Background Background Progressive volumetric
Progressive volumetric changes in the brains of people with changes in the brains of people with schizophrenia have been attributed to a schizophrenia have been attributed to a number of factors. number of factors.
Aims Aims To determine whether
To determine whether glutamatergic changes in patients with glutamatergic changes in patients with schizophrenia correlated with grey-matter schizophrenia correlated with grey-matter losses during the first years of illness. losses during the first years of illness.
Method Method Left anterior cingulate and
Left anterior cingulate and thalamic glutamatergic metabolite levels thalamic glutamatergic metabolite levels and grey-matter volumes were examined and grey-matter volumes were examined in16 patients with first-episode in16 patients with first-episode schizophrenia before and after10 months schizophrenia before and after10 months and 30 months of antipsychotic treatment and 30 months of antipsychotic treatment and in16 healthy participants on two and in16 healthy participants on two occasions 30 months apart. occasions 30 months apart.
Results

Results Higher than normal glutamine
Higher than normal glutamine levels were found in the anterior cingulate levels were found in the anterior cingulate and thalamus of never-treated patients. and thalamus of never-treated patients. Thalamic levels of glutamine were Thalamic levels of glutamine were significantly reduced after 30 months. significantly reduced after 30 months. Limited grey-matter reductions were seen Limited grey-matter reductions were seen in patients at10 months followed by in patients at10 months followed by widespread grey-matter loss at 30 widespread grey-matter loss at 30 months.Parietal and temporallobe greymonths. Parietal and temporallobe greymatter loss was correlated with thalamic matter loss was correlated with thalamic glutamine loss. glutamine loss.
Conclusions Conclusions Elevated glutamine levels
Elevated glutamine levels in never-treated patients followed by in never-treated patients followed by decreased thalamic glutamine and greydecreased thalamic glutamine and greymatter loss in connected regions could matter loss in connected regions could indicate either neurodegeneration or a indicate either neurodegeneration or a plastic response to reduced subcortical plastic response to reduced subcortical activity. activity.
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Systematic reviews of prospective magnetic Systematic reviews of prospective magnetic resonance imaging (MRI) studies of schizoresonance imaging (MRI) studies of schizophrenia have indicated the existence of prophrenia have indicated the existence of progressive volumetric changes in a number of gressive volumetric changes in a number of brain regions (Shenton brain regions (Shenton et al et al, 2001; Steen , 2001; Steen et et al al, 2006) . A number of explanations have , 2006) . A number of explanations have been offered for these changes including been offered for these changes including the effects of medication, a programmed the effects of medication, a programmed loss of neuropil and excitotoxic damage loss of neuropil and excitotoxic damage analogous to that caused by phencyclidine analogous to that caused by phencyclidine in rats (Williamson, 2006) . Proton magin rats (Williamson, 2006) . Proton magnetic resonance spectroscopy ( netic resonance spectroscopy ( 1 1 H-MRS) H-MRS) allows allows in vivo in vivo quantification of glutamaterquantification of glutamatergic metabolite levels at different stages of gic metabolite levels at different stages of illness which could be associated with illness which could be associated with glutamatergic excitotoxicity; such studies glutamatergic excitotoxicity; such studies in patients with schizophrenia have found in patients with schizophrenia have found increased glutamine levels in both the left increased glutamine levels in both the left anterior cingulate and thalamus in neveranterior cingulate and thalamus in nevertreated patients with first-episode schizotreated patients with first-episode schizophrenia and decreased levels of both glutaphrenia and decreased levels of both glutamate and glutamine in the left anterior mate and glutamine in the left anterior cingulate in patients with chronic illness cingulate in patients with chronic illness (Bartha (Bartha et al, et al, 1997; Theberge 1997; Théberge et al, et al, 2002 Théberge et al, et al, , 2002 Théberge et al, et al, , 2003 . Volumetric MRI techniques such 2003) . Volumetric MRI techniques such as voxel-based morphometry (VBM) allow as voxel-based morphometry (VBM) allow the assessment of grey-matter losses that the assessment of grey-matter losses that could be caused by medication effects or could be caused by medication effects or programmed loss of neuropil. Separately, programmed loss of neuropil. Separately, 1 1 H-MRS and VBM, used in a longitudinal H-MRS and VBM, used in a longitudinal study of first-episode schizophrenia, permit study of first-episode schizophrenia, permit comparison of the time evolution of brain comparison of the time evolution of brain abnormalities with that expected through abnormalities with that expected through pathophysiological mechanisms involving pathophysiological mechanisms involving grey-matter loss alone or glutamatergic grey-matter loss alone or glutamatergic losses alone. By combining the two technilosses alone. By combining the two techniques one can examine pathophysiological ques one can examine pathophysiological mechanisms involving both grey-matter mechanisms involving both grey-matter loss and glutamatergic changes such as neuloss and glutamatergic changes such as neuroplasticity or neuropil loss. The purpose of roplasticity or neuropil loss. The purpose of this study was to determine whether glutathis study was to determine whether glutamatergic abnormalities in schizophrenia matergic abnormalities in schizophrenia correlated with grey-matter losses during correlated with grey-matter losses during the first years of illness. the first years of illness.
We predicted that patients experiencing We predicted that patients experiencing a first episode of schizophrenia would have a first episode of schizophrenia would have higher than normal glutamatergic metabohigher than normal glutamatergic metabolite levels on the basis of our previous lite levels on the basis of our previous studies (Bartha studies (Bartha et al et al, , 1997; Theberge 1997; Théberge et al et al, , 2002) . From a previous cross-sectional 2002) . From a previous cross-sectional study of chronic schizophrenia showing study of chronic schizophrenia showing lower than normal glutamine levels in the lower than normal glutamine levels in the anterior cingulate (Theberge anterior cingulate (Théberge et al et al, 2003 (Théberge et al et al, ), , 2003 , glutamatergic metabolites levels and greyglutamatergic metabolites levels and greymatter volumes were expected to decrease matter volumes were expected to decrease after 30 months in patients experiencing a after 30 months in patients experiencing a first episode of schizophrenia and to remain first episode of schizophrenia and to remain unchanged in healthy participants. Furtherunchanged in healthy participants. Furthermore, we predicted that the effect of medimore, we predicted that the effect of medication alone on glutamatergic metabolites cation alone on glutamatergic metabolites and grey-matter volumes would be minimal and grey-matter volumes would be minimal and that disease-related reductions in these and that disease-related reductions in these quantities would become apparent when quantities would become apparent when comparing never-treated patients and comparing never-treated patients and patients treated for approximately 2.5 years patients treated for approximately 2.5 years (30 months), but these parameters would (30 months), but these parameters would not decrease in healthy participants asnot decrease in healthy participants assessed 2.5 years apart. Finally, we expected sessed 2.5 years apart. Finally, we expected that the longitudinal differences in glutamathat the longitudinal differences in glutamatergic metabolites in the anterior cingulate tergic metabolites in the anterior cingulate and thalamus would correlate with the and thalamus would correlate with the grey-matter volume differences in functiongrey-matter volume differences in functionally connected cortical areas, because glutaally connected cortical areas, because glutamatergic losses in a given region can also be matergic losses in a given region can also be attributed to loss of glutamatergic afferents attributed to loss of glutamatergic afferents from another structure, in which case local from another structure, in which case local reductions in glutamatergic metabolites reductions in glutamatergic metabolites could be obtained without local greycould be obtained without local greymatter losses and in response to remote matter losses and in response to remote grey-matter losses. grey-matter losses.
METHOD METHOD
Sixteen never-treated participants experienSixteen never-treated participants experiencing a first episode of schizophrenia and 16 cing a first episode of schizophrenia and 16 healthy participants volunteered for the healthy participants volunteered for the study after the protocol was fully exstudy after the protocol was fully explained, and written informed consent was plained, and written informed consent was obtained according to the guidelines of the obtained according to the guidelines of the Review Board for Health Sciences Research Review Board for Health Sciences Research Involving Human Subjects at the University Involving Human Subjects at the University of Western Ontario in Canada. Participants of Western Ontario in Canada. Participants were recruited by advertisement within the were recruited by advertisement within the community and health network of London, community and health network of London, Ontario. Demographic information about Ontario. Demographic information about each group of participants is summarised each group of participants is summarised in Table 1 . The first MRS assessment of in Table 1 . The first MRS assessment of 12 of the participants with schizophrenia 12 of the participants with schizophrenia and 6 healthy participants was part of a and 6 healthy participants was part of a previous study (Theberge previous study (Théberge et al et al, 2002 12) separated the healthy participants' first and second the healthy participants' first and second examinations. For convenience, the data examinations. For convenience, the data groups are referred to as follows: particigroups are referred to as follows: participants with schizophrenia first assessment pants with schizophrenia first assessment (never treated), (never treated), NT; second assessment NT; second assessment (10 months of treatment), 10 M; third (10 months of treatment), 10 M; third assessment (30 months of treatment), assessment (30 months of treatment), 30 M; healthy participants first assessment, 30 M; healthy participants first assessment, HPAR1; second assessment, HPAR2. HPAR1; second assessment, HPAR2.
All participants were assessed by a psyAll participants were assessed by a psychiatrist using the Structured Clinical Interchiatrist using the Structured Clinical Interview for DSM-IV (SCID; First view for DSM-IV (SCID; First et al et al, 1997) . , 1997). Eleven participants were classified as havEleven participants were classified as having paranoid schizophrenia and five as ing paranoid schizophrenia and five as having undifferentiated schizophrenia. The having undifferentiated schizophrenia. The duration of untreated psychosis for particiduration of untreated psychosis for participants with schizophrenia was evaluated pants with schizophrenia was evaluated and defined as the elapsed time between and defined as the elapsed time between the first examination and the first appearthe first examination and the first appearance of positive symptoms. Symptoms of ance of positive symptoms. Symptoms of participants with schizophrenia were evaluparticipants with schizophrenia were evaluated using the Scale for the Assessment of ated using the Scale for the Assessment of Negative Symptoms (SANS; Andreasen, Negative Symptoms (SANS; Andreasen, 1983a and the Scale for the Assessment ) and the Scale for the Assessment of Positive Symptoms (SAPS; Andreasen, of Positive Symptoms (SAPS; Andreasen, 1983b . The mean parental educational ). The mean parental educational level of the most educated parent was rated level of the most educated parent was rated on a four-point scale for all participants on a four-point scale for all participants (level 1, grade 10 or below; level 2, grades (level 1, grade 10 or below; level 2, grades 11-13; level 3, college 1-3 years; level 4, 11-13; level 3, college 1-3 years; level 4, college 4 years or more). Handedness was college 4 years or more). Handedness was assessed using a questionnaire (Bryden, assessed using a questionnaire (Bryden, 1977 (Bryden, ). 1977 .
Four participants with schizophrenia Four participants with schizophrenia received medications other than antireceived medications other than antipsychotics 1-10 days prior to their first psychotics 1-10 days prior to their first scan (see Table 2 ). For patients receiving scan (see Table 2 ). For patients receiving antipsychotic treatment, chlorpromazine antipsychotic treatment, chlorpromazine equivalent dosages were calculated equivalent dosages were calculated (Bezchlibnyk-Butler & Jeffries, 2002; (Bezchlibnyk-Butler & Jeffries, 2002; Woods, 2003) . At their second assessment, Woods, 2003) . At their second assessment, all patients were receiving atypical antipsyall patients were receiving atypical antipsychotics (not clozapine), with the exception chotics (not clozapine), with the exception of one patient who received haloperidol of one patient who received haloperidol and two who did not receive antipsychotic and two who did not receive antipsychotic medication but were judged to be clinically medication but were judged to be clinically stable. At the final assessment two partistable. At the final assessment two participants were taking clozapine and a third cipants were taking clozapine and a third participant was no longer receiving mediparticipant was no longer receiving medication. cation.
None of the participants had a history None of the participants had a history of head injury or of drug or alcohol misuse of head injury or of drug or alcohol misuse in the year before the scan, or a serious in the year before the scan, or a serious medical illness (according to SCID and medical illness (according to SCID and anatomical MRI). Participants reported anatomical MRI). Participants reported not using substances on the day of the scan; not using substances on the day of the scan; urinalysis was not always performed. urinalysis was not always performed.
MRS and MRI MRS and MRI
All MRI and MRS data were obtained All MRI and MRS data were obtained using a 4.0 T Varian (Palo Alto, California, using a 4.0 T Varian (Palo Alto, California, USA)/Siemens (Erlangen, Germany) scan-USA)/Siemens (Erlangen, Germany) scanner with a Varian Unity Inova console, ner with a Varian Unity Inova console, Siemens Sonata gradients and a circularly Siemens Sonata gradients and a circularly polarised hybrid head resonator (XLR polarised hybrid head resonator (XLR Imaging Inc., London, Ontario, Canada). Imaging Inc., London, Ontario, Canada). The methods of MRI data acquisition and The methods of MRI data acquisition and MRS data acquisition and data processing MRS data acquisition and data processing were identical to those described in a were identical to those described in a previous report by Theberge previous report by Théberge et al et al (2002) .
. These procedures are described briefly below. These procedures are described briefly below.
After a manual adjustment of global After a manual adjustment of global magnetic field uniformity with first-and magnetic field uniformity with first-and second-order shims, a second-order shims, a 2). Voxels were positioned by the scanner operator were positioned by the scanner operator (J.T. or N.A.) based on anatomical land-(J.T. or N.A.) based on anatomical landmarks, as trained by our local neuroanatmarks, as trained by our local neuroanatomy expert (N.R.). Local field uniformity omy expert (N.R.). Local field uniformity and radio frequency pulse power were and radio frequency pulse power were manually optimised for each voxel. The line manually optimised for each voxel. The line shapes of the water-suppressed spectra shapes of the water-suppressed spectra were restored to a Lorentzian form using were restored to a Lorentzian form using a combined QUALITY and eddy current a combined QUALITY and eddy current correction (ECC) lineshape correction correction (ECC) lineshape correction (QUECC; as in Bartha (QUECC; as in Bartha et al et al, 2000 Bartha et al et al, , 2000b . ). Residual water resonances between (4.2-Residual water resonances between (4.2-6.2 ppm) were modelled using a Hankel-6.2 ppm) were modelled using a HankelLanczos singular value decomposition Lanczos singular value decomposition procedure and subtracted (Bartha procedure and subtracted (Bartha et al et al, , 1999) . Before spectral quantification, the 1999). Before spectral quantification, the quality of every spectrum was evaluated quality of every spectrum was evaluated using two visual scales to provide an index using two visual scales to provide an index composed of a number from 1 to 10 (Visual composed of a number from 1 to 10 (Visual Appreciation Scale) and a letter from A to E Appreciation Scale) and a letter from A to E (Baseline and Artefact Scale). The (Baseline and Artefact Scale). The combined scales allow a more structured combined scales allow a more structured determination of spectral quality and are determination of spectral quality and are used in the decision to discard a spectrum used in the decision to discard a spectrum in cases of excessive voluntary or involunin cases of excessive voluntary or involuntary movement by the participant (further tary movement by the participant (further information about these scales is presented information about these scales is presented in Data Supplement 1 to the online version in Data Supplement 1 to the online version of this paper). In this study, we discarded of this paper). In this study, we discarded spectra with a Visual Appreciation Scale spectra with a Visual Appreciation Scale rating lower than 5 and/or a Baseline and rating lower than 5 and/or a Baseline and Artefact Scale rating poorer than B, and Artefact Scale rating poorer than B, and for which the spectral quantification procefor which the spectral quantification procedure described below was unsuccessful (no dure described below was unsuccessful (no metabolite level data produced). Quantificametabolite level data produced). Quantification of the water-suppressed spectra was pertion of the water-suppressed spectra was performed using the Lawson Health Research formed using the Lawson Health Research Institute Fitman spectral analysis suite Institute Fitman spectral analysis suite (Bartha (Bartha et al et al, 1999 (Bartha et al et al, , 2000 (Bartha et al et al, , 1999 (Bartha et al et al, , 2000a , a software ), a software package developed by our group and used package developed by our group and used by us and by other international collaboraby us and by other international collaborators in more than 30 publications. Time tors in more than 30 publications. Time domain fitting of the water-suppressed domain fitting of the water-suppressed spectra used the first 1024 points acquired. spectra used the first 1024 points acquired. The quantification model used The quantification model used a priori a priori knowledge from 12 metabolite solutions knowledge from 12 metabolite solutions and partial prior knowledge for three and partial prior knowledge for three macromolecules and ten broad components macromolecules and ten broad components as described by Bartha as described by Bartha et al et al (1999 Bartha et al et al ( , 2000 Bartha et al et al ( (1999 Bartha et al et al ( , 2000a a) ) (a complete list of the modelled spectral (a complete list of the modelled spectral components can be found in the caption components can be found in the caption to Fig. 2 ). This quantification model using to Fig. 2 ). This quantification model using partial prior knowledge of broad spectral partial prior knowledge of broad spectral components is ideal for our short echo time components is ideal for our short echo time STEAM-localised spectra acquired without STEAM-localised spectra acquired without outer-volume suppression (Bartha outer-volume suppression (Bartha et al et al, , 2000 (Bartha et al et al, , 2000a . The water-unsuppressed spectra ). The water-unsuppressed spectra were lineshape corrected and fitted to a were lineshape corrected and fitted to a single Lorentzian model. Metabolite levels single Lorentzian model. Metabolite levels were obtained by normalising the metabowere obtained by normalising the metabolite amplitude by the corrected amplitude lite amplitude by the corrected amplitude of the water-unsuppressed acquisition of the water-unsuppressed acquisition (further information is presented in Data (further information is presented in Data Supplement 2 to the online version of this Supplement 2 to the online version of this paper). Although other MRS studies prepaper). Although other MRS studies present metabolite levels calculated in this sent metabolite levels calculated in this fashion as 'absolute' concentrations in fashion as 'absolute' concentrations in mol/l or mol/kg mol/l or mol/kg ww ww , we present them as me-, we present them as metabolite levels in arbitrary units owing to tabolite levels in arbitrary units owing to the arbitrary nature of the numerical values the arbitrary nature of the numerical values chosen for quantities such as temperaturechosen for quantities such as temperaturedependent molecular weights and densities dependent molecular weights and densities as well as the assumed water content of difas well as the assumed water content of different brain tissues (grey matter 81%, ferent brain tissues (grey matter 81%, white matter 71%, CSF 100%). These white matter 71%, CSF 100%). These quantities were obtained from the literature quantities were obtained from the literature rather than measured in each individual rather than measured in each individual participant because of the time needed to participant because of the time needed to obtain such measurements. Additional corobtain such measurements. Additional correction for relaxation weighting ( rection for relaxation weighting (T T 1 1 , T , T 2 2 ) ) and diffusion weighting of both metabolites and diffusion weighting of both metabolites and the water reference signals would be and the water reference signals would be needed to claim absolute quantification; needed to claim absolute quantification; however, the magnitude of changes in these however, the magnitude of changes in these tissue parameters required to produce a sigtissue parameters required to produce a significant change in metabolite levels is typinificant change in metabolite levels is typically considered unlikely to be found in cally considered unlikely to be found in brains not affected by neoplasms, and thus brains not affected by neoplasms, and thus these additional corrections are often igthese additional corrections are often ignored. The coefficients of variation of nored. The coefficients of variation of N N--acetylaspartate, glutamate and glutamine acetylaspartate, glutamate and glutamine metabolite levels using this technique (4.0 metabolite levels using this technique (4.0 T, STEAM, TE T, STEAM, TE¼20 ms, 1.5 cm 20 ms, 1.5 cm 3 3 volume of volume of interest) were 8%, 11% and 24% interinterest) were 8%, 11% and 24% interindividual and 7.3%, 8.9% and 16.9% individual and 7.3%, 8.9% and 16.9% intra-individual (Bartha intra-individual (Bartha et al et al, 2000 (Bartha et al et al, , 2000a . ). Only metabolite levels, ratios of glutaOnly metabolite levels, ratios of glutamate to glutamine (Glu/Gln) and macromate to glutamine (Glu/Gln) and macromolecular levels with inter-individual molecular levels with inter-individual coefficients of variation less than 75% were coefficients of variation less than 75% were included in statistical comparisons. In a included in statistical comparisons. In a normally distributed sample this upper normally distributed sample this upper limit guarantees that less than 10% of the limit guarantees that less than 10% of the sample would have negative values. Negasample would have negative values. Negative concentrations are impossible and tive concentrations are impossible and never produced by our quantification rounever produced by our quantification routine. Thus the upper limit criterion prevents tine. Thus the upper limit criterion prevents metabolite levels for which a significant metabolite levels for which a significant proportion of samples have hit the lower proportion of samples have hit the lower detection threshold (not normally distribudetection threshold (not normally distributed) from being included in the statistical ted) from being included in the statistical analysis (which assumes normality). Quananalysis (which assumes normality). Quantities satisfying this upper limit criterion tities satisfying this upper limit criterion included the metabolite levels of included the metabolite levels of N N-acetyl--acetylaspartate, glutamate, glutamine, cholineaspartate, glutamate, glutamine, cholinecontaining compounds, creatine and phoscontaining compounds, creatine and phosphocreatine, phocreatine, myo myo-inositol and taurine for -inositol and taurine for the anterior the anterior cingulate spectra; in addition, cingulate spectra; in addition, scyllo scyllo-inositol -inositol met the criterion in the thalamet the criterion in the thalamic spectra. Macromolecular levels of mic spectra. 30 and M0.90 in the thalamus met the coefficient of variation upper limit the coefficient of variation upper limit criterion as well as the metabolite level criterion as well as the metabolite level Glu/Gln in both regions of interest. Results Glu/Gln in both regions of interest. Results for metabolites not satisfying this upper for metabolites not satisfying this upper limit criterion are not reported. These limit criterion are not reported. These metabolites were nevertheless part of the metabolites were nevertheless part of the spectral quantification template. spectral quantification template.
For the two measurement period data For the two measurement period data (NT and 30M (NT and 30M v. v. HPAR1 and HPAR2) the HPAR1 and HPAR2) the overall layout entailed a 2 overall layout entailed a 26 62 split-plot 2 split-plot factorial design with 'measurement period' factorial design with 'measurement period' being the two-level within-participant factor being the two-level within-participant factor and 'participant group' being the two-level and 'participant group' being the two-level between-participant factor. With our direcbetween-participant factor. With our directional hypotheses on the progression of tional hypotheses on the progression of glutamate and glutamine levels, unidirecglutamate and glutamine levels, unidirectional statistical tests ( tional statistical tests (a a¼0.05) were applied. 0.05) were applied. Significant effects, however, met two-tailed Significant effects, however, met two-tailed criteria throughout (Stevens, 1996) . The criteria throughout (Stevens, 1996) . The time evolution of glutamate and glutamine time evolution of glutamate and glutamine levels for participants with schizophrenia levels for participants with schizophrenia was tested separately from other metabowas tested separately from other metabolites because of our directional hypotheses lites because of our directional hypotheses concerning these metabolites. Here, the concerning these metabolites. Here, the data layout entailed a three-level repeateddata layout entailed a three-level repeatedmeasures design using measurements from measures design using measurements from NT, 10M and 30M. Spectroscopic data for NT, 10M and 30M. Spectroscopic data for which we had no which we had no a priori a priori hypotheses hypotheses (macromolecular levels, the Glu/Gln ratio (macromolecular levels, the Glu/Gln ratio and the set of metabolite levels residual to and the set of metabolite levels residual to glutamate and glutamine) were examined glutamate and glutamine) were examined using multivariate analysis of variance using multivariate analysis of variance (MANOVA) applied region-wise using the (MANOVA) applied region-wise using the 2 26 62 (groups 2 (groups6 6time) split-plot factorial time) split-plot factorial layout. For the patient group, the above layout. For the patient group, the above measures were subjected to a region-wise measures were subjected to a region-wise MANOVA using the aforementioned MANOVA using the aforementioned three-level repeated-measures design. three-level repeated-measures design. Constituent univariate analyses of variance Constituent univariate analyses of variance were applied to the individual variables of were applied to the individual variables of the multivariate set pursuant to significant the multivariate set pursuant to significant parent multivariate results ( parent multivariate results (a a¼0.05). Two-0.05). Twotailed alphas of 0.05 (Hummel & Sligo, tailed alphas of 0.05 (Hummel & Sligo, 1971 1971 Stevens, 1996) were used for the ; Stevens, 1996) were used for the follow-up univariate tests (e.g. the statistical follow-up univariate tests (e.g. the statistical treatment in Jensen treatment in Jensen et al et al, 2004 Jensen et al et al, ). , 2004 . Correlation between metabolite levels of Correlation between metabolite levels of participants with schizophrenia and sympparticipants with schizophrenia and symptoms scores (SANS and SAPS) as well as toms scores (SANS and SAPS) as well as with length of illness and chlorpromazine with length of illness and chlorpromazine equivalent dosage (30M only) were evaluequivalent dosage (30M only) were evaluated using the Pearson product-moment ated using the Pearson product-moment correlation coefficient ( correlation coefficient (P P5 50.001). 0.001).
Voxel-based morphometry maps were Voxel-based morphometry maps were obtained for each participant using SPM2 obtained for each participant using SPM2 (Wellcome Department of Imaging Neuro-(Wellcome Department of Imaging Neuroscience, University College London, UK) science, University College London, UK) and the and the T T 1 1 -weighted images. Images were -weighted images. Images were spatially normalised to the spatially normalised to the T T 1 1 -weighted -weighted template provided by SPM2 (Montreal template provided by SPM2 (Montreal Neurological Institute brain) and segmenNeurological Institute brain) and segmented into grey/white/CSF images with the ted into grey/white/CSF images with the modified model cluster analysis after modified model cluster analysis after correcting for intensity non-uniformity correcting for intensity non-uniformity . Images were . Images were then modulated by the Jacobian determithen modulated by the Jacobian determinants obtained in the normalisation step nants obtained in the normalisation step and finally smoothed using an isotropic and finally smoothed using an isotropic Gaussian kernel (12 mm full width at half Gaussian kernel (12 mm full width at half maximum) maximum) k¼5 were set to explore the 5 were set to explore the hypothesised correlation of grey-matter loss hypothesised correlation of grey-matter loss and glutamine loss. and glutamine loss.
RESULTS RESULTS
The participants' demographic and clinical The participants' demographic and clinical characteristics and data availability are characteristics and data availability are summarised in Tables 1 and 2 . summarised in Tables 1 and 2.
General General 1 1 H-MRS and VBM results H-MRS and VBM results
The proton MRS section of this study The proton MRS section of this study produced 152 spectra: 2 regions per partiproduced 152 spectra: 2 regions per participant cipant6 6((3 time points ((3 time points6 616 participants 16 participants with schizophrenia -3 missing time points) with schizophrenia -3 missing time points) + (2 time points + (2 time points6 616 healthy participants 16 healthy participants7 7 1 missing time point)). Six of these spectra, 1 missing time point)). Six of these spectra, obtained from participants with schizoobtained from participants with schizophrenia, were considered unusable because phrenia, were considered unusable because of excessive voluntary or involuntary moveof excessive voluntary or involuntary movements during the acquisition (Table 1) ; no ments during the acquisition (Table 1) ; no successful quantification was obtained successful quantification was obtained from these six spectra. Discarded spectra from these six spectra. Discarded spectra had spectral quality ratings of 0E, 0E, 4C, had spectral quality ratings of 0E, 0E, 4C, 3E and 10D and one thalamic spectral 3E and 10D and one thalamic spectral acquisition was abandoned before compleacquisition was abandoned before completion owing to breathing-induced phase varition owing to breathing-induced phase variations. All discarded spectra had been ations. All discarded spectra had been obtained from male participants (anterior obtained from male participants (anterior cingulate: two NT, one 10M; thalamus: cingulate: two NT, one 10M; thalamus: one NT, two 10M) and their handedness one NT, two 10M) and their handedness was as follows: anterior cingulate, rightwas as follows: anterior cingulate, righthanded participants exclusively (two NT, handed participants exclusively (two NT, one 10M); thalamus, two right-handed one 10M); thalamus, two right-handed participants (one NT, one 10M) and one participants (one NT, one 10M) and one left-handed participant (10M). left-handed participant (10M).
Mean metabolite levels for both regions Mean metabolite levels for both regions and all groups are presented in Fig. 1 along and all groups are presented in Fig. 1 along with group standard deviations and statiswith group standard deviations and statistics for significant differences (macromoletics for significant differences (macromolecule levels for both regions and all groups cule levels for both regions and all groups are presented in Data Supplement 3, and are presented in Data Supplement 3, and group standard deviations of metabolite group standard deviations of metabolite levels and minimum detectable percentage levels and minimum detectable percentage difference between groups in Data Suppledifference between groups in Data Supplement 4 to the online version of this paper). ment 4 to the online version of this paper). A typical spectrum from the anterior cingu-A typical spectrum from the anterior cingulate of a participant with schizophrenia is late of a participant with schizophrenia is shown in Fig. 2 , together with the spectral shown in Fig. 2 , together with the spectral model and components. Fitted line widths model and components. Fitted line widths of unsuppressed water signals and time doof unsuppressed water signals and time domain main N N-acetylaspartate area signal-to-noise -acetylaspartate area signal-to-noise ratios ratios are presented in Data Supplement 5 are presented in Data Supplement 5 to the online version of this paper. The to the online version of this paper. The distribution of thalamic glutamine levels is distribution of thalamic glutamine levels is presented in Fig. 3 for all participant presented in Fig. 3 for all participant groups. groups.
Voxel-based morphometry used 77 Voxel-based morphometry used 77 anatomical volumes (3 time points anatomical volumes (3 time points6 616 16 participants with schizophrenia -3 missing participants with schizophrenia -3 missing time points)+(2 time points time points)+(2 time points6 616 healthy 16 healthy participants). Group standard deviation participants). Group standard deviation estimates for grey-matter 'concentrations' estimates for grey-matter 'concentrations' and minimum detectable difference beand minimum detectable difference between groups, based on data from a tween groups, based on data from a selected volume of interest in the superior selected volume of interest in the superior temporal gyrus are presented in Data temporal gyrus are presented in Data Supplement 4, and the distribution of Supplement 4, and the distribution of VBM grey-matter concentrations is shown VBM grey-matter concentrations is shown in Fig. 3 . in Fig. 3 .
Statistical comparisons Statistical comparisons
Proton MRS and VBM data were compared Proton MRS and VBM data were compared between participants with schizophrenia and between participants with schizophrenia and healthy participants (between participants healthy participants (between participants) ) and among participants with schizophrenia and among participants with schizophrenia at different time points (within partiat different time points (within participants). A summary of all statistical comcipants). A summary of all statistical comparisons is presented in Data Supplement parisons is presented in Data Supplement 6 and details of significant VBM findings 6 and details of significant VBM findings are presented in Data Supplements 7 and are presented in Data Supplements 7 and 8. Significant findings are presented below. 8. Significant findings are presented below.
Between-participant comparisons Between-participant comparisons
Anterior cingulate glutamine levels were Anterior cingulate glutamine levels were significantly elevated among participants significantly elevated among participants with schizophrenia (NT) compared with with schizophrenia (NT) compared with healthy participants (HPAR1) (see Fig. 1 ). healthy participants (HPAR1) (see Fig. 1 ). This predicted result was embedded in a This predicted result was embedded in a significant main effect of groups pursuant significant main effect of groups pursuant to the routine tests of the 2 to the routine tests of the 26 62 split-plot 2 split-plot factorial analysis ( factorial analysis (F F¼4.67, d.f. 4.67, d .f.¼1,26, 1,26, P P¼0.04). The 2 0.04). The 26 62 analysis revealed a signifi-2 analysis revealed a significant effect for group at the univariate level cant effect for group at the univariate level in metabolite levels of in metabolite levels of N N-acetylaspartate -acetylaspartate (see Fig. 1 ) and macromolecular levels (see Fig. 1 .035). These group differences were 0.035). These group differences were not significant at the multivariate level of not significant at the multivariate level of analysis; although not ignored, they are analysis; although not ignored, they are presented with this associated caveat. presented with this associated caveat.
Left thalamic glutamate and glutamine Left thalamic glutamate and glutamine levels showed significantly higher glutalevels showed significantly higher glutamine in participants with schizophrenia mine in participants with schizophrenia (NT) than in healthy participants (HPAR1) (NT) than in healthy participants (HPAR1) (see Fig. 1 ), but no significant difference in (see Fig. 1 ), but no significant difference in glutamate levels. The predicted elevation in glutamate levels. The predicted elevation in level of glutamine for the patients' first level of glutamine for the patients' first measurement period was considered as emmeasurement period was considered as embedded in a significant (routinely combedded in a significant (routinely computed) group puted) group6 6time interaction ( time interaction (F F¼5.76, 5.76, d.f. d.f.¼1,27, 1,27, P P¼0.024), and main effect of 0.024), and main effect of time ( time (P P¼0.02). Univariate split-plot factor-0.02). Univariate split-plot factorial analysis of thalamic metabolite levels ial analysis of thalamic metabolite levels residual to glutamate and glutamine, residual to glutamate and glutamine, macromolecular levels and the Glu/Gln macromolecular levels and the Glu/Gln ratio showed a significant group effect for ratio showed a significant group effect for the metabolite level of taurine (see Fig. 1 ), the metabolite level of taurine (see Fig. 1 ), whereby participants with schizophrenia whereby participants with schizophrenia had lower levels than healthy participants. had lower levels than healthy participants. Note that Levene's test for equality of error Note that Levene's test for equality of error variances disclosed no significant difference variances disclosed no significant difference for anterior cingulate and thalamic glutamate for anterior cingulate and thalamic glutamate and glutamine, a statistical bias consideration and glutamine, a statistical bias consideration when comparing groups of unequal size when comparing groups of unequal size (Box, 1953 (Box, , 1954 Milligan (Box, 1953 , 1954 Milligan et al et al, 1987) . , 1987). Between-group comparisons of greyBetween-group comparisons of greymatter volume changes (VBM) showed matter volume changes (VBM) showed significant differences between the last significant differences between the last assessment of healthy participants and assessment of healthy participants and participants with schizophrenia (HPAR2 participants with schizophrenia (HPAR24 4 30M) but not in other comparisons 30M) but not in other comparisons (HPAR1 (HPAR14 4NT, HPAR1 NT, HPAR15 5NT, HPAR2 NT, HPAR25 5 30M) using corrected 30M) using corrected t t-statistics ( -statistics (a a¼0.05, 0.05, 3 2 8 3 2 8 AUTHOR'S PROOF AUTHOR'S PROOF (8) 25 (8) 25 (8) 27 (8) 27 (8) 29 (12) 29 (12) 32 (12) 32 (12) Gender, Gender, n n Female  Female  2  2  2  2  2  2  2  2  2  2   Male  Male  14  14  14  14  14  14  14  14  14  14 Handedness, Handedness, n n k k¼5). Two small regions of significant 5). Two small regions of significant grey-matter reduction were located in the grey-matter reduction were located in the left superior temporal gyrus (BA 22, left superior temporal gyrus (BA 22, k k¼77) and the left caudate head ( 77) and the left caudate head (k k¼10). 10).
Right-handed
Right-handed 12 12 12 12 12 12 13 13 13 13 Left-handed Left-handed 3 3 3 3 3 3 3 3 3 3 Ambidextrous Ambidextrous 1 1 1 1 1 1 0 0 0 0 Educational
Within-participant comparisons (three-level) Within-participant comparisons (three-level)
The three-level repeated-measures analysis The three-level repeated-measures analysis of glutamine and glutamate levels, in the of glutamine and glutamate levels, in the anterior cingulate and thalamus respecanterior cingulate and thalamus respectively, yielded no significant effect. There tively, yielded no significant effect. There were insufficient residual degrees of freedom were insufficient residual degrees of freedom (measure battery-to-participant ratio (measure battery-to-participant ratio 5 51) to 1) to perform a three-level repeated-measures perform a three-level repeated-measures multivariate analysis of anterior cingulate multivariate analysis of anterior cingulate metabolite levels residual to glutamate metabolite levels residual to glutamate and glutamine, macromolecular levels and and glutamine, macromolecular levels and Glu/Gln; however, this was performed sucGlu/Gln; however, this was performed successfully with the corresponding thalamic cessfully with the corresponding thalamic metabolite levels. Multivariate (thalamus metabolite levels. Multivariate (thalamus only) and univariate three-level repeatedonly) and univariate three-level repeatedmeasures analyses revealed no significant measures analyses revealed no significant effect for any of these measurements (the effect for any of these measurements (the Huynh-Feldt non-sphericity correction Huynh-Feldt non-sphericity correction was applied for these tests) in both the antewas applied for these tests) in both the anterior cingulate and thalamus. rior cingulate and thalamus.
The three-level within-group compariThe three-level within-group comparisons of VBM data from participants with sons of VBM data from participants with schizophrenia (NT, 10M, 30M) yielded sigschizophrenia (NT, 10M, 30M) yielded significantly different regions for NT nificantly different regions for NT4 410M, 10M, NT NT4 430M and 10M 30M and 10M4 430M (corrected 30M (corrected a a¼ 0.05, 0.05, k k¼5, d.f. 5, d.f.¼2,24). Figure 4 presents 2,24). Figure 4 presents the distribution of regions of reduced the distribution of regions of reduced grey-matter volume (NT grey-matter volume (NT4 430M) super-30M) superimposed on a cortical surface rendering. imposed on a cortical surface rendering. Regions with significant grey-matter volume Regions with significant grey-matter volume reductions (NT reductions (NT4 430M) include cortical 30M) include cortical regions of the frontal lobe (middle frontal regions of the frontal lobe (middle frontal gyrus: BA 46, 8 and 9; medial frontal gyrus: gyrus: BA 46, 8 and 9; medial frontal gyrus: BA 6 and 8; inferior frontal gyrus: BA46, 9 BA 6 and 8; inferior frontal gyrus: BA46, 9 and 44) bilaterally, the bilateral temporal and 44) bilaterally, the bilateral temporal lobe (BA 38, 39, 42, 21 and 22) , the bilateral lobe (BA 38, 39, 42, 21 and 22) , the bilateral parietal lobe (BA 7, 40, 31 and 39), the parietal lobe (BA 7, 40, 31 and 39), the limbic lobe (BA 28 and 31 (posterior cingulimbic lobe (BA 28 and 31 (posterior cingulate), hippocampus and amygdala), the late), hippocampus and amygdala), the right caudate and right thalamus. right caudate and right thalamus.
Within-participant comparisons (two-level) Within-participant comparisons (two-level)
The split-plot factorial multivariate analysis The split-plot factorial multivariate analysis of anterior cingulate macromolecular levels, of anterior cingulate macromolecular levels, Glu/Gln and the set of metabolite levels Glu/Gln and the set of metabolite levels residual to glutamate and glutamine yielded residual to glutamate and glutamine yielded a significant effect for time only ( a significant effect for time only (F F¼4.681, 4 As the 0.006). As the group of participants with schizophrenia group of participants with schizophrenia had a smaller variance, and lower had a smaller variance, and lower n n owing owing to missing/excluded data, the lack of signifto missing/excluded data, the lack of significant effects for this measure was not a icant effects for this measure was not a statistical artefact (Milligan statistical artefact (Milligan et al et al, 1987) . , 1987). The split-plot factorial MANOVA on The split-plot factorial MANOVA on thalamic metabolite levels residual to glutathalamic metabolite levels residual to glutamate and glutamine, macromolecular levels mate and glutamine, macromolecular levels and Glu/Gln yielded no significant effect. and Glu/Gln yielded no significant effect. Univariate split-plot factorial analysis of Univariate split-plot factorial analysis of the same measurements nevertheless rethe same measurements nevertheless revealed a significant effect for time in two vealed a significant effect for time in two macromolecular levels: both M1.50 macromolecular levels: both M1. Grouping of VBM data from particiGrouping of VBM data from participants with schizophrenia according to subpants with schizophrenia according to subtype (paranoid type (paranoid v.
v. undifferentiated) in a undifferentiated) in a 2 26 62 split-plot factorial design did not 2 split-plot factorial design did not produce any significant effect for group produce any significant effect for group using a corrected using a corrected a a¼0.05 and 0.05 and k k¼5. Grey-5. Greymatter loss across time (NT matter loss across time (NT v. v. 30M) was 30M) was not significantly different between subtypes not significantly different between subtypes (corrected (corrected P P5 50.05, 0.05, k k¼5). 5). Based on the grey-matter, white-matter Based on the grey-matter, white-matter and CSF segmentation procedure perand CSF segmentation procedure performed on the anterior cingulate and thalaformed on the anterior cingulate and thalamic MRS volumes of interest for the mic MRS volumes of interest for the calculation of tissue content correction calculation of tissue content correction factors used in spectral quantification, a factors used in spectral quantification, a technique akin to traditional grey-matter technique akin to traditional grey-matter volume measurements, the amount of volume measurements, the amount of 3 2 9 3 2 9 AUTHOR'S PROOF AUTHOR'S PROOF (145) 196 (145) 154 (150) 154 (150) CPZeq, chlorpromazine equivalent. CPZeq, chlorpromazine equivalent. P¼0.01, 0.01, n n¼73) 73) which is a macromolecular level that was which is a macromolecular level that was not included in the planned statistical ananot included in the planned statistical analyses (s.d. lyses (s.d.4 475%). However, upon 75%). However, upon post post hoc hoc examination no significant difference examination no significant difference in M2.05 levels was found between any in M2.05 levels was found between any group of participants. group of participants.
Correlation of grey-matter loss in partiCorrelation of grey-matter loss in participants with schizophrenia (NT cipants with schizophrenia (NT 7 730M) 30M) and antipsychotic dosage at 30M showed and antipsychotic dosage at 30M showed no significant results using a corrected no significant results using a corrected a a value of 0.05. However, significant correlavalue of 0.05. However, significant correlation was found in three areas of the brain tion was found in three areas of the brain using an exploratory uncorrected using an exploratory uncorrected a a of of 0.001: left frontal lobe (precentral gyrus, 0.001: left frontal lobe (precentral gyrus, BA 6, BA 6, x y z x y z 7 750, 2, 28; 50, 2, 28; P P5 50.001, 0.001, t t¼8.38); left frontal lobe (superior gyrus, 8.38); left frontal lobe (superior gyrus, BA 10, BA 10, x y z x y z 7 718, 64, 18; 18, 64, 18; P P5 50.001, 0.001, t t¼6.59); right frontal lobe (inferior gyrus, 6.59); right frontal lobe (inferior gyrus, BA 9, BA 9, x y z x y z¼32, 16, 28; 32, 16, 28; P P5 50.001, 0.001, t t¼4.93). 4.93). Grey-matter loss (NT Grey-matter loss (NT 7 730M) did not 30M) did not show any significant correlation with the show any significant correlation with the 3 3 0 3 3 0 AUTHOR'S PROOF AUTHOR'S PROOF resonance and residual water peaks); (c) macromolecular spectral components; 13 unidentified broad resoresonance and residual water peaks); (c) macromolecular spectral components; 13 unidentified broad reso- time elapsed between NT and 30M assesstime elapsed between NT and 30M assessments using an uncorrected ments using an uncorrected a a of 0.001. of 0.001. Correlation of grey-matter loss (NT Correlation of grey-matter loss (NT 7 730M) assessed by VBM with reduction 30M) assessed by VBM with reduction in thalamic glutamine (NT in thalamic glutamine (NT 7 730M) was 30M) was found in four areas of the brain when using found in four areas of the brain when using an uncorrected an uncorrected a a of 0. . The correlation between left superior temporal correlation between left superior temporal gyrus grey-matter concentration loss and gyrus grey-matter concentration loss and left thalamic glutamine loss is presented in left thalamic glutamine loss is presented in Fig. 5 (  Fig. 5 (r r¼0.741 , 0.741, n n¼14, 14, P P5 50.001). 0.001).
Given the finding of positive correlation Given the finding of positive correlation between thalamic glutamine loss and greybetween thalamic glutamine loss and greymatter volume loss from the VBM analysis, matter volume loss from the VBM analysis, we expected a similar positive correlation we expected a similar positive correlation between voxel grey-matter loss (first scan between voxel grey-matter loss (first scan to last scan), as assessed during the grey/ to last scan), as assessed during the grey/ white/CSF segmentation procedure of the white/CSF segmentation procedure of the MRS analysis, and glutamine loss (first scan MRS analysis, and glutamine loss (first scan to last scan) in patients, and no correlation to last scan) in patients, and no correlation in controls. No significant correlation was in controls. No significant correlation was found overall. In the anterior cingulate of found overall. In the anterior cingulate of patients (NT patients (NT 7 730M) a trend towards a 30M) a trend towards a significant negative correlation was obsignificant negative correlation was observed ( served (r r¼7 70.453, 0.453, P P¼0.120, two-tailed, 0.120, two-tailed, n n¼13), but no significant result was ob-13), but no significant result was observed in controls ( served in controls (r r¼7 70.149, 0.149, P P¼0.597, 0.597, two-tailed, two-tailed, n n¼15). No significant correla-15). No significant correlation was observed in the thalamus of tion was observed in the thalamus of patients ( patients (r r¼0.158, 0.158, P P¼0.590, two-tailed, 0.590, two-tailed, n n¼14) and controls ( 14) and controls (r r¼0.027, 0.027, P P¼0.925, 0.925, two-tailed, two-tailed, n n¼15). 15).
DISCUSSION DISCUSSION
Glutamatergic alterations Glutamatergic alterations
Proton MRS showed significantly increased Proton MRS showed significantly increased levels of glutamine in both the left anterior levels of glutamine in both the left anterior cingulate and the left thalamus of nevercingulate and the left thalamus of nevertreated participants with schizophrenia treated participants with schizophrenia compared with healthy participants. These compared with healthy participants. These results are akin to the medial prefrontal results are akin to the medial prefrontal findings of Bartha findings of Bartha et al et al (1997) in a comple-(1997) in a completely different cohort of patients and contely different cohort of patients and controls, and partially replicate the findings trols, and partially replicate the findings of Theberge of Théberge et al et al (2002 Théberge et al et al ( ), who used an over-(2002 , who used an overlapping cohort of participants mostly comlapping cohort of participants mostly composed of the same patients (12 of 16 NT) posed of the same patients (12 of 16 NT) and a different group of controls (6 of 16 and a different group of controls (6 of 16 HPAR1). The results are consistent with a HPAR1). The results are consistent with a recent report of increased glutamine in the recent report of increased glutamine in the anterior cingulate of healthy participants anterior cingulate of healthy participants administered a low dose of ketamine, a administered a low dose of ketamine, a drug known to reliably produce schizodrug known to reliably produce schizophrenia-like symptoms (Rowland phrenia-like symptoms (Rowland et al et al, , 2005) , and with a report of increased gluta-2005), and with a report of increased glutamatergic metabolites in the medial frontal matergic metabolites in the medial frontal cortex of adolescents at high risk of develcortex of adolescents at high risk of developing schizophrenia (Tibbo oping schizophrenia (Tibbo et al et al, 2004) . , 2004). Glutamine levels did not significantly Glutamine levels did not significantly decrease in the left thalamus in participants decrease in the left thalamus in participants with schizophrenia whose symptoms were with schizophrenia whose symptoms were stabilised with medication for 10 months, stabilised with medication for 10 months, suggesting that medication or clinical status suggesting that medication or clinical status did not affect the findings. The absence of did not affect the findings. The absence of significant correlation between medication significant correlation between medication levels or clinical assessments and glutamine levels or clinical assessments and glutamine levels also suggest that these variables do levels also suggest that these variables do not explain the findings. Decrease in thalanot explain the findings. Decrease in thalamic glutamine within a period of 30 mic glutamine within a period of 30 months in participants with schizophrenia months in participants with schizophrenia 3 31 3 31 AUTHOR'S PROOF AUTHOR'S PROOF could be explained by an excitotoxic procould be explained by an excitotoxic process. However, glutamine levels did not decess. However, glutamine levels did not decrease below healthy levels in either regions crease below healthy levels in either regions of interest. This contrasts with lower-thanof interest. This contrasts with lower-thannormal glutamate and glutamine levels normal glutamate and glutamine levels found in the anterior cingulate of patients found in the anterior cingulate of patients with chronic schizophrenia (duration of with chronic schizophrenia (duration of illness 15 years) (Theberge illness 15 years) (Théberge et al et al, 2003) . If , 2003) . If excitotoxicity is responsible for glutamine excitotoxicity is responsible for glutamine decreases from elevated first-episode levels decreases from elevated first-episode levels to lower than normal levels in patients with to lower than normal levels in patients with chronic illness, this study suggests that chronic illness, this study suggests that more than 30 months must elapse for its more than 30 months must elapse for its manifestation. This result also contrasts manifestation. This result also contrasts with the higher than normal thalamic levels with the higher than normal thalamic levels of glutamine found in patients with chronic of glutamine found in patients with chronic schizophrenia (Theberge schizophrenia (Théberge et al, et al, 2003); 2003) ; however, the majority of these patients were however, the majority of these patients were being treated with conventional rather than being treated with conventional rather than atypical antipsychotics for 10 years or more, atypical antipsychotics for 10 years or more, which might account for the difference. which might account for the difference.
Anterior cingulate glutamine levels in Anterior cingulate glutamine levels in never-treated participants with schizonever-treated participants with schizophrenia did not significantly decrease upon phrenia did not significantly decrease upon follow-up, suggesting that glutamatergic follow-up, suggesting that glutamatergic activity remains elevated in this region for activity remains elevated in this region for at least 30 months. As expected, no signifiat least 30 months. As expected, no significant difference in glutamine levels was obcant difference in glutamine levels was observed between the initial and follow-up served between the initial and follow-up examination in healthy participants, sugexamination in healthy participants, suggesting that ageing does not affect normal gesting that ageing does not affect normal glutamatergic activity over a period of 30 glutamatergic activity over a period of 30 months. We did not observe any significant months. We did not observe any significant difference in difference in N N-acetylaspartate levels be--acetylaspartate levels between participants with schizophrenia and tween participants with schizophrenia and healthy participants at first assessment or healthy participants at first assessment or follow-up, which is consistent with studies follow-up, which is consistent with studies using the same (Bartha using the same (Bartha et al, et al, 1997; 1997; Theberge Théberge et al, et al, 2002 , 2003 ) or similar 2002 , 2003 or similar methods (short echo time MRS and spectral methods (short echo time MRS and spectral analysis without non-physical baseline analysis without non-physical baseline modelling). modelling).
Volumetric alterations Volumetric alterations
Voxel-based morphometry uncovered no Voxel-based morphometry uncovered no significant grey-matter volume difference significant grey-matter volume difference in the anterior cingulate and thalamus in the anterior cingulate and thalamus when comparing never-treated participants when comparing never-treated participants with schizophrenia and healthy partiwith schizophrenia and healthy participants. This suggests that significant differcipants. This suggests that significant differences in glutamine levels observed in neverences in glutamine levels observed in nevertreated participants compared with healthy treated participants compared with healthy participants are unlikely to be secondary to participants are unlikely to be secondary to a programmed loss of neuropil (Selemon a programmed loss of neuropil (Selemon et et al al, 1999) prior to onset of symptoms or to , 1999) prior to onset of symptoms or to other neurodevelopmental processes involother neurodevelopmental processes involving early grey-matter loss. However, eleving early grey-matter loss. However, elevated levels of glutamine in the early vated levels of glutamine in the early stages of untreated schizophrenia suggest stages of untreated schizophrenia suggest a pre-existing dysregulation of the limbic a pre-existing dysregulation of the limbic basal ganglia-thalamocortical pathway basal ganglia-thalamocortical pathway (Alexander (Alexander et al et al, 1990) , the origin of which , 1990), the origin of which is not apparent from this study. No is not apparent from this study. No grey-matter volume difference was detected grey-matter volume difference was detected between the two healthy participant assessbetween the two healthy participant assessments 30 months apart. This suggests that ments 30 months apart. This suggests that grey-matter reductions related to normal grey-matter reductions related to normal ageing are unlikely to play a part in our ageing are unlikely to play a part in our findings. findings.
Both the 10-month and 30-month Both the 10-month and 30-month assessments of participants with schizoassessments of participants with schizophrenia showed significant reductions in phrenia showed significant reductions in grey matter compared with the first grey matter compared with the first (never-treated) assessment. After 10 months (never-treated) assessment. After 10 months of treatment and stabilisation of symptoms, of treatment and stabilisation of symptoms, only a small cluster of voxels showed signifonly a small cluster of voxels showed significantly reduced grey-matter volume in the icantly reduced grey-matter volume in the left precuneus. After 30 months of treatleft precuneus. After 30 months of treatment the significant reductions were widement the significant reductions were widespread and had expanded to include spread and had expanded to include regions of the frontal, temporal, parietal regions of the frontal, temporal, parietal and limbic lobes. These observations are and limbic lobes. These observations are similar to those of previous studies (Shenton similar to those of previous studies (Shenton et al et al, 2001; Thompson , 2001; Thompson et al et al, 2001; Gogtay , 2001; Gogtay et al et al, 2004; Honea , 2004; Honea et al et al, 2005) , particularly , 2005), particularly those looking at patients with first-episode those looking at patients with first-episode disorder. Even after a short period of treatdisorder. Even after a short period of treatment (10 months) and stabilisation of ment (10 months) and stabilisation of symptoms, grey-matter volume reductions symptoms, grey-matter volume reductions were observed, which suggests that antiwere observed, which suggests that antipsychotic medication might be partly repsychotic medication might be partly responsible for the losses. However, the sponsible for the losses. However, the progressive nature of the grey-matter losses progressive nature of the grey-matter losses demonstrated at the 30-month assessment, demonstrated at the 30-month assessment, when both clinical status and antipsychotic when both clinical status and antipsychotic treatment had remained practically untreatment had remained practically unchanged, suggests that the additional losses changed, suggests that the additional losses are disease-related. Late effects of antiare disease-related. Late effects of antipsychotic medication on cortical volume psychotic medication on cortical volume are also a possibility. are also a possibility.
Excitotoxicity or plasticity? Excitotoxicity or plasticity?
It is curious that no grey-matter loss was It is curious that no grey-matter loss was observed in regions where elevated observed in regions where elevated glutamine was detected in never-treated glutamine was detected in never-treated participants with schizophrenia; this was participants with schizophrenia; this was expected, assuming the action of a glutamaexpected, assuming the action of a glutamatergic excitotoxic process. It is possible that tergic excitotoxic process. It is possible that the use of a 12 mm smoothing kernel in the the use of a 12 mm smoothing kernel in the VBM analysis reduced our sensitivity to VBM analysis reduced our sensitivity to grey-matter changes in small structures grey-matter changes in small structures (White (White et al et al, 2001) within the MRS regions , 2001) within the MRS regions of interest. However, traditional grey/ of interest. However, traditional grey/ white/CSF segmentation performed on the white/CSF segmentation performed on the MRS volume of interest only also did not MRS volume of interest only also did not detect significant grey-matter loss in the detect significant grey-matter loss in the anterior cingulate and thalamus. Detected anterior cingulate and thalamus. Detected regions of grey-matter loss, such as the regions of grey-matter loss, such as the dorsolateral prefrontal cortex and superior dorsolateral prefrontal cortex and superior temporal gyrus, are closely connected with temporal gyrus, are closely connected with both the thalamus and the anterior cinguboth the thalamus and the anterior cingulate. Interestingly, the posterior cingulate late. Interestingly, the posterior cingulate -one of the regions demonstrating signifi--one of the regions demonstrating significant reduction in grey matter at the 30 cant reduction in grey matter at the 30 months assessment -is one of the first months assessment -is one of the first regions to incur excitotoxic damage after regions to incur excitotoxic damage after an acute administration of glutamate an acute administration of glutamate N N--methylmethyl-D D-aspartate receptor antagonist in -aspartate receptor antagonist in the rat model of schizophrenia of Olney the rat model of schizophrenia of Olney & Farber (1995) . Other schizophrenia & Farber (1995) . Other schizophrenia models have proposed that regions of the models have proposed that regions of the dorsolateral prefrontal cortex and temporal dorsolateral prefrontal cortex and temporal lobe cortex regulate the limbic basal ganglobe cortex regulate the limbic basal ganglia-thalamocortical circuit which includes lia-thalamocortical circuit which includes the anterior cingulate and thalamus the anterior cingulate and thalamus (O'Donnell & Grace, 1998) . Thus a pro- (O'Donnell & Grace, 1998) . Thus a programmed loss of neuropil in these cortical grammed loss of neuropil in these cortical regions prior to the onset of symptoms regions prior to the onset of symptoms could be associated with a secondary could be associated with a secondary excitotoxic process in the limbic excitotoxic process in the limbic basal basal ganglia-thalamocortical circuit. How ganglia-thalamocortical circuit. However, ever, in our study no lower than normal greyin our study no lower than normal greymatter volume consistent with loss of neumatter volume consistent with loss of neuropil was observed at the initial assessment ropil was observed at the initial assessment in those cortical regions. Thalamic input in those cortical regions. Thalamic input has an important role in directing the neuhas an important role in directing the neuroplastic processes during cortical developroplastic processes during cortical development (Jafari ment (Jafari et al et al, 2007) and probably has a , 2007) and probably has a significant role in adult cortical plasticity significant role in adult cortical plasticity (Weinberger, 1995) . The reciprocal connec- (Weinberger, 1995) . The reciprocal connections between the thalamus and cortical tions between the thalamus and cortical regions are a potential conduit by which regions are a potential conduit by which decreasing thalamic activity (evidenced in decreasing thalamic activity (evidenced in this study by a progressive reduction in this study by a progressive reduction in glutamine) could lead to a plastic response. glutamine) could lead to a plastic response. The finding of significantly correlated The finding of significantly correlated superior temporal lobe grey-matter loss superior temporal lobe grey-matter loss and thalamic glutamine loss supports this and thalamic glutamine loss supports this interpretation. interpretation.
Limitations Limitations
Some limitations should be acknowledged. Some limitations should be acknowledged. Proton MRS measurements of glutamate Proton MRS measurements of glutamate and glutamine reflect the combined intraand glutamine reflect the combined intraand extraneuronal concentration within a and extraneuronal concentration within a somewhat coarse region of interest despite somewhat coarse region of interest despite the use of high-field systems. Increases in the use of high-field systems. Increases in glutamine concentration may not reflect glutamine concentration may not reflect increases in glutamatergic activity if a increases in glutamatergic activity if a problem exists with the conversion of problem exists with the conversion of glutamine to glutamate in the astrocytic glutamine to glutamate in the astrocytic compartment of the glutamate-glutamine compartment of the glutamate-glutamine cycle. However, there is no consistent evicycle. However, there is no consistent evidence for such enzymatic abnormality in dence for such enzymatic abnormality in schizophrenia. Glucose metabolism also inschizophrenia. Glucose metabolism also influences glutamatergic neurotransmission fluences glutamatergic neurotransmission by synthesising 15-20% of the glutamate by synthesising 15-20% of the glutamate entering the glutamate-glutamine cycle entering the glutamate-glutamine cycle (Hertz (Hertz et al et al, 1999) . The single-voxel MRS , 1999). The single-voxel MRS localisation technique used produced highlocalisation technique used produced highquality data from the anterior cingulate quality data from the anterior cingulate and thalamus yet did not permit the acquiand thalamus yet did not permit the acquisition of MRS data from other regions of sition of MRS data from other regions of the brain potentially implicated in schizothe brain potentially implicated in schizophrenia within a reasonable examination phrenia within a reasonable examination time. Macromolecular signals have been time. Macromolecular signals have been hypothesised by some to potentially hypothesised by some to potentially influence glutamate and glutamine meainfluence glutamate and glutamine measurements. However, surements. However, post hoc post hoc correlations correlations of glutamine levels and overlapping macroof glutamine levels and overlapping macromolecular levels do not show a significant molecular levels do not show a significant link, with the exception of thalamic glutalink, with the exception of thalamic glutamine levels and macromolecular level mine levels and macromolecular level M2.05 which show a loose association. M2.05 which show a loose association. This association is not sufficient to explain This association is not sufficient to explain significant findings in thalamic glutamine. significant findings in thalamic glutamine. Correlation with a greater number of Correlation with a greater number of overlapping components would have been overlapping components would have been necessary in order to explain the glutamine necessary in order to explain the glutamine findings because of the fairly wide spread in findings because of the fairly wide spread in chemical shift of glutamine's gamma and chemical shift of glutamine's gamma and beta multiplets. Such a quantification artebeta multiplets. Such a quantification artefact would probably have occurred in fact would probably have occurred in anterior cingulate data as well, yet no coranterior cingulate data as well, yet no correlation was found between glutamine and relation was found between glutamine and macromolecular levels in this region. The macromolecular levels in this region. The number of participants in this study is fairly number of participants in this study is fairly small owing to the complexity of following small owing to the complexity of following them up over several years. Steen them up over several years. Steen et al et al (2005) suggest that 39 patients and 29 (2005) suggest that 39 patients and 29 controls are needed to obtain 80% statisticontrols are needed to obtain 80% statistical power to detect a 10% difference in cal power to detect a 10% difference in N N--acetylaspartate. Consequently, the number acetylaspartate. Consequently, the number of participants might not have of participants might not have been suffibeen sufficient to detect differences in metabolites cient to detect differences in metabolites such as such as N N-acetylaspartate. The VBM tech--acetylaspartate. The VBM technique may have limited ability to detect nique may have limited ability to detect grey-matter volume differences in certain grey-matter volume differences in certain parts of the brain, and the use of parts of the brain, and the use of large large smoothing kernels may render the analysis smoothing kernels may render the analysis sensitive to partial volume effects. Future sensitive to partial volume effects. Future studies should verify the observed progresstudies should verify the observed progressive loss of grey matter with more sive loss of grey matter with more conconventional but time-consuming volumetric ventional but time-consuming volumetric techniques. techniques.
